Dermatomyositis and lupus may share symptoms in some cases. Here's what you need to know about these autoimmune conditions.

Dazukibart, a type I interferon inhibitor, reduced dermatomyositis disease severity while maintaining a well-tolerated safety ...

Effective management of dermatomyositis requires a coordinated, multidisciplinary team to address its complex and systemic nature. Collaboration between specialists ensures comprehensive care and ...

Dermatomyositis is a rare inflammatory disease characterized by muscle weakness and skin rash. The exact cause is unknown, ...

Treatment with dazukibart, a monoclonal antibody targeting interferon beta, yielded a rapid reduction in dermatomyositis disease activity in adults with skin-predominant and muscle-predominant ...